Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the National Kidney Foundation 2024 Spring Clinical Meetings

WALTHAM, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that additional data supporting XPHOZAH (tenapanor) will be presented at the National Kidney Foundation (NKF) 2024 Spring Clinical Meetings, to be held May 14-18, 2024, in Long Beach, California. XPHOZAH, the first and only phosphate absorption inhibitor (PAI), is approved by the U.S. Food and Drug Administration to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. XPHOZAH offers a different mechanism of action that blocks phosphate absorption at the primary pathway and is administered as a single tablet taken twice daily.

Title: Tenapanor Treatment Added to Phosphate Binders Improved Long-Term Serum Phosphate (P) Control as Measured by Reduction in Average Daily P Area Under the Curve
Authors: Kevin J. Martin, David M. Spiegel, Yang Yang, David Rosenbaum, Susan Edelstein, Laura Williams
Poster Number: 239
Date/Time: May 15, 2024, from 5:30 PM to 7:00 PM PDT (UTC –7)

Title: Treatment Response to Tenapanor Categorized by Age and Comorbidities: A Post Hoc Analysis of the PHREEDOM Study
Authors: Daniel Weiner, David M. Spiegel, Yang Yang, David Rosenbaum, Susan Edelstein
Poster Number: 243
Date/Time: May 15, 2024, from 5:30 PM to 7:00 PM PDT (UTC –7)

Title: Patient Perception of Phosphate-Lowering Treatment Regimen Improves Adherence to Therapy
Authors: Amy Mosman, Susan Edelstein, David M. Spiegel, Suling Zhao, David Rosenbaum
Poster Number: 240
Date/Time: May 15, 2024, from 5:30 PM to 7:00 PM PDT (UTC –7)

In addition to the poster presentations during NKF Spring Clinical Meetings, Ardelyx is sponsoring an Exhibitor Showcase titled: “A New Paradigm: Rethinking Hyperphosphatemia Management,” on May 17, 2024, from 8:30-9:05 AM PDT, where David M. Spiegel, MD and Lisa Gutekunst MSEd, RD, CSR, CDN, FNKF, will discuss first-in-class PAI, XPHOZAH. The presentation will review the XPHOZAH mechanism of action, efficacy and safety data from the Phase 3 clinical trial program and will include a discussion about the clinical application of XPHOZAH as add-on therapy for the many dialysis patients on a phosphate binder with serum phosphorus levels above guideline-established targets.